The Phase 2 iMMagine-1 data are from a May 1, 2025 data cutoff date, including all 117 patients with a median follow-up of 12.6 months and a minimum follow-up of four months after treatment with ...

Data from the Phase 2 iMMagine-1 study of anito-cel showed 97% overall response rate (ORR) and 68% complete response/stringent complete response (CR/sCR) in patients with relapsed or refractory ...